Winway Health Desk
Aurobindo is finding it difficult to satisfy the FDA, or the...
India’s Aurobindo, which has yet to meet FTC terms to complete a $1 billion deal to buy a significant chunk of Sandoz U.S. generics...
The New York Proton Center
The New York Proton Therapy Center is the first facility of its kind in New York State. The $300 million center, eight years in...
Takeda opens €130M plant to produce dengue vaccine it has yet...
Takeda has yet to file for approval of its vaccine candidate to treat dengue but it now has a €130 million plant and 200...
Another California venture capitalist jumps ship to a startup
Busy Burr, newly-appointed president and chief commercial officer, Carrot
In early September, Renee Ryan, veteran healthcare venture capitalist with Johnson & Johnson Innovation – JJDC...
Daiichi Sankyo sues Seattle Genetics over antibody-drug conjugate technology
A Japanese drugmaker is suing a U.S.-based biotech company over the latter’s claims to intellectual property dating back to a now defunct partnership between...
FDA Approves Fluzone High-Dose Quadrivalent (Influenza Vaccine) for Adults 65 Years...
PARIS, Nov. 4, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for Fluzone High-Dose Quadrivalent...
FDA Approves Ziextenzo (pegfilgrastim-bmez), a Biosimilar to Neulasta
FDA Approves Ziextenzo (pegfilgrastim-bmez), a Biosimilar to Neulasta
Holzkirchen, Nov. 5, 2019 – Sandoz, a Novartis division and a global leader in biosimilars, today announced...
Jeopardy host Alex Trebek partners with AZ, Celgene-backed pancreatic cancer group...
TV game show host Alex Trebek is known for his stoicism and bemused retorts, but more recently for his forthright reveal of his pancreatic...
Eli Lilly, Boehringer shake up diabetes deal to focus on hot...
Eli Lilly and Boehringer Ingelheim have stormed to a market-leading position with their SGLT-2 diabetes drug Jardiance, and they’re pushing that med to the...
After years-long delay, Novartis’ Sandoz finally wins Neulasta biosimilar nod
Back in 2016, FDA stiff-armed Novartis and its biosimilar version of Amgen's Neulasta. After three long years and one batch of new study data,...
